Britelite™ plus is a homogeneous, ultra-high sensitivity luciferase reporter gene assay system quantitation of firefly luciferase expression in mammalian cells. britelite plus was designed to provide maximum signal intensity assays requiring utmost sensitivity, and is suitable use in a 96-, 384-, or 1536-well microplate format. With a signal half-life of 30 minutes, britelite plus is ideal for:

• Smaller scale sample analysis where maximum sensitivity is needed
• High throughput assays employing continuous processing methodology

britelite plus benefits:

• Very high assay sensitivity
• Designed continuous process systems
• Suitable higher density microplates such as 384-well and 1536-well plates
• Ideal smaller-scale sample analysis when maximum sensitivity is needed
• Odor free
• Convenient storage conditions (2 - 8 °C)

As with all members of Revvity's Lites suite of luciferase detection reagents, britelite plus offers superior performance in an easy-to-use format, providing following benefits:

• Convenient One-Step Processing: No washes required - simply mix, incubate and read
• Enhanced Stability: All lites reagents are designed extended storage at 2 - 8 °C
• No DTT: Unlike most luciferase detection reagents, lites products do not contain DTT, eliminating toxic hazards and need hood work
• Excellent Z' Values: All lites products offer robust, sensitive performance, with high signal-to-background ratios and excellent Z'values

At Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.